BioCorRx acquires FDA-approved opioid withdrawal drug Lucemyra from USWM LLC

BioCorRx Inc.

Upfront purchase price of $400,000 paid via seller retention of 50% of net sales and net distributable profits until capped.
BioCorRx issued 500,000 shares of common stock and a warrant for 500,000 shares at $1.00 exercise price, 2-year term.
Lucemyra is first and only non-opioid FDA-approved medication for opioid withdrawal; BioCorRx expects meaningful sales and positive cash flow.
BioCorRx will pay a low single-digit royalty to USWM on future sales; no direct cash payment at closing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.